Biological drugs have improved the management of immune-mediated inflammatory diseases (IMIDs) despite being associated with important safety issues such as immunogenicity, infections, and malignancies in real-world settings.
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project
Trifirò, Gianluca
;Isgrò, Valentina;L'Abbate, Luca;Moretti, Ugo;Lora, Riccardo;Sabaini, Alberto;Tuccori, Marco;
2021-01-01
Abstract
Biological drugs have improved the management of immune-mediated inflammatory diseases (IMIDs) despite being associated with important safety issues such as immunogenicity, infections, and malignancies in real-world settings.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
BioDrugs 2021.pdf
accesso aperto
Tipologia:
Versione dell'editore
Licenza:
Creative commons
Dimensione
3.06 MB
Formato
Adobe PDF
|
3.06 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
